Federal Judge Blocks Trump Administration’s Medicaid Funding Restrictions Targeting Planned Parenthood 
Intel Rejects TSMC’s Allegations of Trade-Secret Leaks as Legal Battle Escalates 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium 
Asian Currencies Steady as Markets Await Fed Rate Decision; Indian Rupee Hits New Record Low 
UPS MD-11 Crash Prompts Families to Prepare Wrongful Death Lawsuit 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Judge Dismisses Charges Against Comey and Letitia James After Ruling on Prosecutor’s Appointment 
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
UN General Assembly Demands Russia Return Ukrainian Children Amid Ongoing Conflict 
Oil Prices Hold Steady as Ukraine Tensions and Fed Cut Expectations Support Market 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
Johnson & Johnson (J&J) has sued drug distributors and a pharmacy seeking to stop the sale of counterfeit versions of its HIV drugs, and at least $25 million in damages from each defendant.
Patients complaining about receiving the wrong pills in their prescription bottles led J&J to discover widespread counterfeiting, as did the voluntary return of hundreds of bottles of counterfeit pharmaceuticals from one of the defendants, distributor ProPharma Distribution LLC.
Following Gilead Sciences Inc.'s lawsuit in January, the firm said it became aware of the sale of counterfeit versions of its HIV medications. Symtuza, a multi-drug combination treatment, as well as Prezcobix, Prezista, and Edurant, are among the medications at issue.
J&J claims that counterfeit bottles occasionally included a different HIV medicine than what was advertised on the label and that one counterfeit bottle contained the strong antipsychotic Seroquel.
The defendants include ProPharma, Safe Chain Solutions LLC, and Scripts Wholesale Inc, as well as drugstore operator I Care Pharmacy 14 and the business' individual proprietors.
According to the lawsuit, I Care Pharmacy had a physical location in New York City that was closed down immediately after a fraudulent transaction was found.
J&J believes the pharmacy is linked to a criminal counterfeiting network that is still operational in New York City, dispensing hazardous counterfeit HIV medication.
